mollie hemingway face shivaani kummar ohsu email. Under his leadership, the Knight Cancer Institute is actively engaged in doing so., Brian Druker, M.D., Knight Cancer Institute director, JELD-WEN Chair of Leukemia Research; investigator, Howard Hughes Medical Institute. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. The provider's speciality is Internal Medicine with a focus in Medical Oncology How many years of experience does Dr. Shivaani Kummar have? Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. Sort. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. Cited by. 2001-2022 Oregon Health & Science University. Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. Yourinsurancecompany will also be able to inform you of any copayments, coinsurance, or deductibles that will be your responsibility. Each study answers scientific questions and tries to find better ways to prevent, diagnose or treat diseases like cancer. DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, Journal of clinical oncology 27 (16), 2705. By Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh Carlson | American Journal of Managed Care ABSTRACTThe tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. Claire Yoshida, M.S.N., A.C.N.S.-B.C., A.C.H.P.N. Notice of Privacy Practices Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . Articles Cited by Public access. 23() 'Oregon Health & Science University Knight Cancer Institute(OHSU)' BAL0891 1 Shivaani Kummar (Principal Investigator, PI), OHSU 'Mary Crowley Cancer Research . She received her medical degree from Lady Hardinge Medical College and has been in practice for . OHSU Knight Cancer Institute is a national leader in cancer research and training and well-known for its ability to turn cancer research discoveries into new cancer treatments. Select a country/territory to view shared publications and projects. Dr. Kummar completed a residency at Emory University. 1. cleveland, tx funeral homes share dancing on ice app for ipad tweet exhaustive list of cushing's syndrome symptoms share. Across OHSU, doctors and researchers are reimagining early disease detection. PHYSICIAN HELPLINE Phone: 1-866-742-4811 Fax: 650-320-9443 Monday - Friday, 8 a.m. - 5 p.m. Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. As an oncologist, Dr. Kummar manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. Having someone who understands the challenges is helpful.. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. 2001-2023 OHSU. Office 3181 SW Sam Jackson Park Rd Portland, OR 97239 Phone+1 503-280-1223 Is this information wrong? Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. 2001-2023 OHSU. middlesex county community college nursing program nj CET membership is open to anyone at OHSU with an interest in advancing drug discovery and development. Our ability to move these projects forward and to take on new projects is limited by the available resources. OHSU Knight Cancer Institute leaders include some of the most distinguished doctors and scientists in the world. shivaani kummar ohsu email. . Administrative Coordinator, Denise Hopkins Ashok Muralidaran, M.D., discusses how his passions inspire his work as a pediatric cardiac surgeon. Accueil; Solution; Tarif; PRO; Mon compte; France; Accueil; Solution Professor of Medicine, OHSU. She runs early phase clinical trials evaluating new treatments while ensuring highest standards of patient safety. Shivaani Kummar: STUDY00021766: . These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. This conversation is with Shivaani Kummar, MD (professor, oncology), who joined the Stanford faculty in January 2015. Its staff of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Palliative Care Administrative Assistant. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC Box 29017 Portland, OR 97296, Portland Office 2020 SW 4th Avenue Suite 900 Portland, OR 97201. & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content. Study Purpose. Nature reviews Drug discovery 9 (11), 843-856. Her research interests focus on developing novel therapies for cancer. We are thrilled he is able to co-lead this new venture. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. We have a number of clinical trials investigating promising new strategies to treat cancer. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Get to know some of the resear. Notice of Privacy Practices Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. Education & Training Oregon Health & Science University Fellowship, Hematology and Medical Oncology, 1995 - 1997 New York Presbyterian Hospital (Columbia Campus) Residency, Internal Medicine, 1990 - 1993 Harvard Medical School Class of 1989 OHSU is an equal opportunity affirmative action institution. February 17, 2023. 2022 ASCO Annual Meeting - Poster Session . . And to train and inspire the next generation of doctors and scientists. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Over the past six months, a multidisciplinary team has been coordinating patient experience, drug delivery, staffing schedules and equipment needed to support the range of clinical trials offered in the unit that span 14 different cancer disease groups. OHSU is an equal opportunity affirmative action institution. Leadership The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. Shivaani Kummar (Principal Investigator, PI), OHSU Mary Crowley Cancer Research, Montefiore Medical Center 4 1 . The OHSU Knight Cancer Institute has expanded its cancer research and care facilities to include a unit dedicated to serving patients participating in early-phase clinical trials. massachusetts vs washington state. OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. In 2020, 470 Oregon residents from 28 counties consented to participate in clinical trial activities with the Knight Cancer Institute. Together they have built a strong record of discovery, innovation and care. Only fill in if you are not human. Year; Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. Support the Abortion Care and Training Fund. My patients. Dive into the research topics where Shivaani Kummar is active. OHSU is an equal opportunity affirmative action institution. The couple says their ultimate goal is to develop new effective therapies for cancer. Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. What sort of projects are you working on right now? Cancer Early Detection Advanced Research Center, Adolescent and Young Adult Oncology Program, Social and Emotional Side Effects of Cancer, International Alliance for Early Cancer Detection (ACED), Lisa M. Coussens, M.D. Shivaani Kummar. BAL0891 . The units team of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. The institute is involved with more than 400 clinical trials, including 113 early-phase trials. At the end of the day, we need to develop better treatment for cancer patients and the only way to build that is through collaboration within OHSU and with other academic centers, biotech and pharma companies., Team science can be a buzz word. What excites you about coming to work in the morning? She shares our urgency to better understand how research and drug development can help the patients who desperately need better treatments, today.. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX February 17, 2023. (Getty Images), Communications Manager, OHSU Knight Cancer Institute, Husband-wife team from Stanford University tapped to lead two cancer programs at OHSU, OHSU leading effort to make cancer trials more inclusive, Making Hepatitis C care easier when treatment seems impossible, Pill for skin disease also curbs excessive drinking, OHSU clinical trial tests exercise for multiple sclerosis treatment. The two will co-lead the institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. S Kummar, A Chen, J Ji, Y Zhang, JM Reid, M Ames, L Jia, M Weil, K Do, D Wilsker, J Ji, J Zlott, T Freshwater, RJ Kinders, J Collins, AP Chen, Journal of Clinical Oncology 33 (30), 3409. Together they form a unique fingerprint. OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD (OHSU/Joe Rojas-Burke), The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. Spray Foam Equipment and Chemicals. Administrative Coordinator, Margaret Rogers Administrative Coordinator, Ingrid Studebaker Together their goal is to find a cure for cancer. Our ability to collaborate with academics and industries across the globe will be paramount to our success in developing new drugs for patients. Shivaani Kummar, M.D., FACP Expertise Cancer Special focus Medical Oncology and Hematology Email this page Print this page About me Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. Uncategorized . She currently practices at Oregon Health And Sciencs University Primary Care Clinic and is affiliated with Stanford Health Care. They say they shared an interest in cancer drug discovery and development that grew after their marriage. Due to Covid-19 pandemic, the 2020 Symposium was postponed to 2021. Hung, M.D. Sort by citations Sort by year Sort by title. OHSU Foundation P.O. Malhotras background is in chemical biology and drug development with a strong expertise in medicinal chemistry, including small molecule synthesis. Clinical trials Drug development oncology. Accepting new patients Post author By ; aleko lm137 manual Post date July 1, 2022; police clearance certificate in saudi arabia . Overall: 4.7 out of 5 Shivaani Kummar Dr. Kummar was recently appointed as Division Chief of Hematology and Oncology, and co-Director of the Center for Experimental Therapeutics, at the Oregon Health and Science University in Portland, Oregon. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. Password. Developing new treatments for cancer is a complex, multidisciplinary process that truly takes a village. These topic labels come from the works of this person. You may also qualify for Phase 1 Program trials. The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development. Shivaani Kummar Aim: Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of. For help with all referral needs and questions, visit Referring Physicians. He has the mindset and the clear vision to make that mindset a reality., Malhotra agrees: We speak the same language. bard college music faculty. . Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer Research', 'Montefiore Medical Center' 4 1 . The unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. what was bolivar's ultimate goal? edu h-index 8546 Citations 49 h-index 1996 2023 Research activity per year Overview Fingerprint Network Grants (5) Publications (174) Similar Profiles (1) If you made any changes in Pure these will be visible here soon. Shivaani Kummar, M.D., FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. (h.c.), Ph.D., FAACR. Title. BYLINE. Dr. Their mission is clear: To give patients excellent care. The OHSU Knight Cancer Institute is part of regional, national and international research partnerships, offering patients local access to the latest advances and clinical trials. Affiliated Hospitals Medical Group Practices Practice Location 3181 Sw Sam Jackson Park Rd Portland, Oregon 97239-3011 Map and Directions Phone: (503) 314-7168 Office Hours: Monday - Friday: 8:00 AM - 5:00 PM Saturday - Sunday: Closed We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . Tom Sellers was named lead research officer at OHSU Knight Cancer Institute. Charles D. Blanke, M.D., F.A.C.P., F.A.S.C.O. The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. Abstracts & Presentations. 23 () 'Oregon Health & Science University Knight Cancer Institute (OHSU)' BAL0891 1 . OHSU is an equal opportunity affirmative action institution. Want to join the faculty at the Knight Cancer Institute? Expanding scientific knowledge is a key mission of OHSU, Oregons only academic health center. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. The provider is located at 3181 Sw Sam Jackson Park Rd Portland, Or 97239 and the phone number is (503) 314-7168 Which is Dr. Shivaani Kummar specialty? (h.c.), Ph.D., FAACR. Username or E-mail. Of that, $160 million was used for the Knight Cancer Research Building, which opened in 2018, and $40 million was used to build expanded capacity for clinical trial care in CHH2, which opened in 2019. Shivaani Kummar 1 2 , Apurva K Srivastava 3 , Tony Navas 3 4 , Fabiola Cecchi 5 6 , Young H Lee 5 7 , Donald P Bottaro 5 , Sook Ryun Park 1 8 , Khanh T Do 1 9 , Woondong Jeong 1 10 , Barry C Johnson 1 , Andrea R Voth 1 , Larry Rubinstein 11 , John J Wright 1 , Ralph E Parchment 3 , James H Doroshow 1 12 , Alice P Chen 13 Clinical trials are research studies that test how well new medicines or treatments work in people.